We hypothesize that soluble amyloid beta-protein (Abeta) oligomers are key effectors of neurotoxicity and? may be a primary cause of Alzheimer's disease (AD). Consequently, inhibition of Abeta Oligomerization? is an attractive strategy for preventing and treating AD. We propose to use a systematic, rational? design approach for preparation and structure-activity studies of Abeta Oligomerization inhibitors. We? will focus our efforts on inhibitors of early Abeta(1-42) oligomers termed """"""""paranuclei."""""""" We choose early? Abeta(1-42) oligomers as our primary target because Abeta(1-42) is particularly linked to AD and because? inhibition of early assembly of Abeta(1-42) will alleviate the neurotoxic effects, both of the oligomers? themselves and of the larger neurotoxic assemblies, protofibrils and fibrils, for which paranuclei are? precursors. Our design in based on recent experimental and modeling data that delineate structural? features of paranucleus assembly, including primary-quaternary structure relationships and? conformation of the C-terminus of Abeta(1-42). This region is responsible directly for the enhanced? toxicity and distinct Oligomerization pattern of Abeta(1-42) relative to the more abundant alloform,? Abeta(1-40). The inhibitor design process is tightly integrated with the structural and biological projects? within the overall Program. The design process not only will benefit from the structural data? generated by the Program members, but also will feed back into structural studies and provide? further understanding of how particular regions and residues in Abeta interact with each other to form? oligomers.
Showing the most recent 10 out of 68 publications
